

check for prior art

JAN-26-05 14:14 FROM-Merchant & Gould

6123329081

T-650 P.003/010 F-517

Date Mailed: October 20, 1998

Sheet 1 of 1

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 7885.35USWO	Application Number: 09/125,751
	Applicant: PODSTAD et al	
	Filing Date: Int Filing Date March 12, 1997	Group Art Unit: Unknown

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,925,922	May 15, 1990	Byers et al.			

FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
<i>SM</i>	EP 129 434	✓	Sept. 6, 1989	EPO		
<i>SM</i>	EP 256 471	✓	Feb. 24, 1988	EPO		
	W/O 88/07369	✓	July 28, 1988	PCT		
<i>SM</i>	WO 94/02016	✓	Feb. 3, 1994	PCT		
	W/O 91/09058	✓	June 27, 1991	PCT		
<i>SM</i>	WO 95/34817	✓	Dec. 21, 1995	PCT		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
<i>SM</i>	1989	Abstract of Accession no. 90659782 Cancerlit, "Fourth International Conference on Monoclonal Antibody Immunocjugates for Cancer", March 30 to April 1, 1989, San Diego, CA, UCSD Cancer Center.
	1992	Abstract of Crowe J.B. et al.; <i>Int. Journ. of cancer</i> , July 9, 1992; Vol. 51, no. 2.
<i>SM</i>	1994	Dialog Information Service, File 159, Cancerlit, Dialog accession no. 01046200, Cancerlit accession no. 94290389, Lemoli RM et al: "Positive selection of hematopoietic CD34+ stem cells provides 'indirect purging' of CD34- lymphoid cells and this purging efficiency is increased by anti-CD2 and anti-CD30 immunotoxins", Bone Marrow Transplant 13(4):465-71, 1994.
<i>SM</i>	1994	Dialog Information Service, File 159, Cancerlit, Dialog accession no. 01018250, Cancerlit accession no. 94084695, Mydathon AT et al: "Comparison of two antibody-based methods for elimination of breast cancer cells from human bone marrow", Cancer Res 54(1):205-14, 1994.
	1991	Dialog Information Service, File 159, Cancerlit, Dialog accession no. 00800246, Cancerlit accession no. 91348943, Tocco R. et al: "Production and Characterization of two Immunotoxins Specific for M2B Anti-Leukemia", <i>Int. J. Cancer</i> 49(2):310-6, 1991.
<i>SM</i>	1986	Dialog Information Service, File 159, Cancerlit, Dialog accession no. 00447849, Cancerlit accession no. 85110572, Tuszynski AO et al: "Elimination of Murine Erythroleukemic Stem Cells with a Novel Anti-Erythroid Antibody Conjugated to Ricin A-chain: A Model for Studies of Bone-Marrow Transplantation Therapy", <i>Int. J. Cancer</i> 37(2):263-73, 1986.
<i>SM</i>	1996	Dialog Information Service, File 159, Cancerlit, Dialog accession no. 01268628, Cancerlit accession no. 97001812, Kvalheim G. et al: "Purging of tumor cells from leukapheresis products: experimental and clinical aspects", <i>J. Hematother.</i> 5(4):427-36, 1996.

RECEIVED
CENTRAL FAX CENTER
JAN 26 2005

Not considered

EXAMINER <i>Juan Lopez</i>	DATE CONSIDERED 1/8/07
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Date Mailed: October 30, 1998

Sheet 2 of 2

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 7885.55USWO	Application Number: 09/125,751
	Applicant: FODSTAD et al.	
	Filing Date: Int'l Filing Date March 13, 1997	Group An Unit: Unknown

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
OTHER DOCUMENTS (including Author, Title, Date, Periodic Pages, Etc.)						
Sayed 3/30/00	1986	Michael J. Bjorn, et al.; "Antibody-Pseudomonas Biotinylated A Conjugates Cytotoxic to Human Breast Cancer Cells in Vitro"; <i>Cancer Research</i> , July 1986; pp. 3262-3267.				
	1989	Im c. Anderson, et al.; "Elimination of Malignant Clonogenic Breast Cancer Cells from Human Bone Marrow"; <i>Cancer Research</i> , pp. 4659-4664.				
	1991	K.C. O'Brian, MS, et al.; "Elimination of Clonogenic Breast Cancer Cells from Human Bone Marrow"; <i>Cancer</i> , 1991; pp. 1272-1278.				
	1993	C.L. Tyer, et al.; "Breast Cancer Cells are Effectively Purged from Peripheral Blood Progenitor cells Using an Immunomagnetic Technique"; Abstract to First meeting of International Society for Hematotherapy and Graft Engineering, Orlando, FL, 1993.				
	1992	Flornozo Schipe, et al.; "Ribosome-Inactivating Proteins from Plants: Present Status and future Prospects"; <i>Bio/Technology</i> , April 1992; Vol. 10, pp. 403-412.				
	1993	Luigi Barbieri, et al.; "Ribosome-inactivating proteins from plants"; <i>Biochimica et Biophysica Acta</i> , 1993; pp. 237-242.				
	1994	R.M. Lemoli, et al.; "Positive selection of hematopoietic CD34+ stem cells provides 'indirect purging' of CD34- lymphoid cells and the purging efficiency is increased by anti-CD2 and anti-CD30 immunotoxins"; <i>Bone Marrow Transplantation</i> , 1994; pp. 465-471.				
	1992	L.J. Diehl, et al.; "Detection of Tumor Cells in Bone Marrow of Patients with Primary Breast Cancer: A Prognostic Factor for Distant Metastasis"; <i>Journal of Clinical Oncology</i> , 1992; pp. 1534-1539.				
	1993	Arne T. Mikkelsen, et al.; "Elimination of Small Cell Lung Cancer Cells from Human Bone Marrow with Immunotoxins"; <i>Cancer Research</i> , 1993; pp. 3784-3788.				

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608; draw line through citation if not in conformance and not considered. Include copy of this form for need communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Date Mailed: October 30, 1998

Sheet 1 of 2

FORM 1449 INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 7889.55USWO	Application Number: 09/123,751
	Applicant: FODSTAD et al.	
	Filing Date: Int. Filing Date: March 12, 1997	Group Art Unit: Unknown

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,322,678	Jun. 21, 1994	Morgan, Jr. et al.			
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
	1993	William P. Peters, et al.; "High-Dose Chemotherapy and Autologous Bone Marrow Support as Consolidation After Standard-Dose Adjuvant Therapy for High-Risk Primary Breast Cancer"; <i>Journal of Clinical Oncology</i> , June 1993; Vol. 11, No. 6, pp.1132-1143.				
	1994	James O. Armitage, M.D.; "Bone Marrow Transplantation"; <i>New England Journal of Medicine</i> , March 24, 1994; Vol. 330, No. 12, pp. 621-638.				
	1990	Thomas V. Munn, et al.; "Contamination of Peripheral Blood Stem Cell Harvests by Circulating Neuroblastoma Cells"; <i>Blood</i> , 1990; Vol. 76, No. 9, pp. 1879-1883.				
	1993	Amy A. East, et al.; "Detection and Viability of Tumor Cells in Peripheral Blood Stem Cell Collections From Breast Cancer Patients Using Immunocytochemical and clonogenic Assay Techniques"; <i>Blood</i> , 1993; Vol. 82, No. 9, pp. 2605-2610.				
	1993	Malcolm R. Richman, et al.; "Gene-marking to trace origin of relapse after autologous bone-marrow transplantation"; <i>Leucem</i> , 1993; pp. 85-86.				
	1991	John G. Grivins, M.D., et al.; "Immunologic Purging of Marrow Assessed by PCR Before Autologous Bone Marrow Transplantation for B-Cell Lymphoma"; <i>New England Journal of Medicine</i> , November 28, 1991; Vol. 324, No. 22, pp. 1525-1533.				
	1994	Elizabeth J. Signell, et al.; "Release of Tumor Cells from Bone Marrow"; <i>Blood</i> , February 1, 1994; pp. 620-625.				
	1994	Welfram Bruggen, et al.; "Mobilization of Tumor Cells and Hematopoietic Progenitor Cells into Peripheral Blood of Patients With Solid Tumors"; <i>Blood</i> , 1994; Vol. 83, No. 3, pp. 636-640.				
	1992	Ger J. Strous, et al.; "Angiogenin-Type Glycoproteins"; <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 1992; pp. 57-92.				
	1986	Lou de Loff, et al.; "The Use of Monoclonal Antibodies for the Pathological Diagnosis of Lung Cancer"; In: E.J.H. Hansen (ed), <i>Lung Cancer: Basic and Clinical Aspects</i> ; Boston: Martinus Nijhoff Publishers, 1986; pp. 31-48.				
	1992	Aslak Godal, et al.; "Immunotoxins directed Against the High-Molecular-Weight Melanoma-Associated Antigen. Identification of Potent Antibody-Toxin Conjugates"; <i>Int. J. Cancer</i> , 1992; pp. 631-633.				
	1978	V.D. Courtney, et al.; "An In Vivo Colony Assay For Human Tumors Grown in Immune-Suppressed Mice and Treated In Vivo with Cytotoxic Agents"; <i>Br. J. Cancer</i> , 1978; pp. 261-268.				
	1992	M.Y. Wang, et al.; "An effective immunomagnetic method for bone marrow purging in T cell malignancies"; <i>Bone Marrow Transplantation</i> , 1992; pp. 319-323.				
	1994	Anne T. Myklebust, et al.; "Comparison of Two Antibody-based Methods for Elimination of Breast Cancer Cells from Human Bone Marrow"; <i>Cancer Research</i> , 1994; pp. 202-214.				
	1993	Connie J. Exter; "Peripheral Blood Stem Cells Reach New Heights"; <i>Blood</i> , 1993; pp. 1937-1939.				
	1994	Elizabeth J. Signell, et al.; "Transplantation of Enriched CD34-Positive Autologous Marrow Into Breast Cancer Patients Following High-Dose Chemotherapy: Influence of CD34-Positive Peripheral-Blood Progenitors and Growth Factors on Engraftment"; <i>Journal of Clinical Oncology</i> , 1994; Vol. 12, No. 1, pp. 28-38.				

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with RPEP 602; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

Substitute Disclosure Statement Form (PTO-1448)

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

JAN-26-05

14:15

~~FROM~~ Merchant & Gould

6123328081

T-660 P.006/010 F-517

Date Mailed: December 3, 1998

Sheet 1 of 1

FORM 1049* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 7885.55USWO	Application Number: 09/125,751
	Applicant: FOOSTAD, et al	
	Filing Date: Init Filing Date March 12, 1997	Group Art Unit: Unknown

[illegible]

*Duplicate
Signed 3/30/80*

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for need communication to the Applicant.	

***Substitute Disclosure Statement Form (PTO-1449)**

Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Date Mailed: October 12, 1999

Sheet 1 of 2

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 7885.55USWO	Application Number: 09/123,731
	Applicant: FODSTAD, et al.	
	Filing Date: October 30, 1998	Group Art Unit: 1643

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,098,097	Mar. 10, 1992	Hermstein et al.			
	5,536,644	Jul. 16, 1996	Ullman et al.			
	5,374,531	Dec. 20, 1994	Jensen			
	5,256,532	Oct. 26, 1993	Melnick et al.			
	5,264,344	Nov. 23, 1993	Saeth			
	5,424,213	Jun. 13, 1995	Mougin			
	5,491,068	Feb. 13, 1996	Benjamin et al.			
	5,514,340	May 7, 1996	Lensdorp et al.			
	5,624,815	Apr. 29, 1997	Grant et al.			
	4,857,432	Aug. 15, 1989	Ho			
	4,752,569	Jun. 21, 1988	Teruzaki et al.			
	5,019,497	May 28, 1991	Olsson			
	4,659,673	Apr. 21, 1987	Forrest et al.			
	5,422,377	Jul. 6, 1995	Connolly et al.			
	4,219,411	Aug. 26, 1980	Yen et al.			
	4,710,472	Dec. 1, 1987	Satt et al.			
	4,920,061	Apr. 24, 1993	Peyman et al.			
	4,510,244	Apr. 9, 1985	Parfitt et al.			
	5,340,719	Aug. 23, 1994	Hajek et al.			
	5,326,696	Jul. 5, 1994	Chang			
	5,405,784	Apr. 11, 1995	Van Hoegaerden			
	5,219,763	Jun. 15, 1993	Van Hoegaerden			
	5,194,300	Mar. 16, 1993	Choung			
	5,290,707	Mar. 1, 1994	Wood			
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
	018 552	Oct. 1, 1980	EPO			
	395 355	Oct. 31, 1990	EPO			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Date Mailed: October 12, 1999

Sheet 2 of 3

FORM 1449 INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 7885.55USWO	Application Number: 09/125,751
	Applicant: FODSTAD, et al.	
	Filing Date: October 30, 1998	Group Art Unit: 1643

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
	WO 90/07380	Jul. 12, 1990	PCT			
	WO 90/10692	Sep. 20, 1990	PCT			
	WO 91/15766	Oct. 7, 1991	PCT			
	95/24648	Sep. 14, 1995	PCT			
	WO A1 94/07139	Mar. 31, 1994	PCT			
	94/07138	Mar. 31, 1994	PCT			
	098 534	Jan. 18, 1984	EPO			
	339 769	Nov. 2, 1989	EPO			
	131 934	Jan. 23, 1985	EPO			
	WO 91/01368	Feb. 7, 1991	PCT			
	WO 92/04961	Apr. 2, 1992	PCT			
	WO 91/09938	Jul. 11, 1991	PCT			
	403960	Jun. 14, 1990	EPO			
	241 042	Oct. 14, 1987	EPO			
	WO 94/07142	Mar. 31, 1994	PCT			
	2638849	May 11, 1990	France			
	3811566	Oct. 27, 1988	Germany			
	537 827	Apr. 21, 1993	EPO			
	WO 96/01777	Oct. 10, 1996	PCT			

Relevant
Signed
3/20/00

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 809; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1448)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Date Mailed: October 12, 1999

Sheet 3 of 3

PTO 1449 INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number:	Application Number:
	7883 SJUSWO	69/125,751
	Applicant: FODSTAD, et al.	
	Filing Date: October 30, 1998	Group Art Unit:

OTHER DOCUMENTS (Including Author, Title/Date, Pertinent Pages, Etc.)		
1989	D. Pilling, et al.: "The kinetics of interaction between lymphocytes and magnetic polymer particles" <i>National Library of Medicine, File Medicine, Medicine accession no. 90010163</i> ; Sept. 1, 1989; 124(1) pp. 235-41.	
1991	R.M. Leven, et al.: "Immunomagnetic bead isolation of megakaryocytes from guinea-pig marrow: effect of recombinant interleukin-6 on size, ploidy and cytoplasmic composition" <i>National Library of Medicine, File Medicine, Medicine accession no. 07671620</i> ; Br J Haematol Mar 1991; 77 (3), pp. 267-273.	
January 1993	BIO/TECHNOLOGY, Volume 11, Bjorn-Ivar Hultman, et al., "Application of Magnetic Beads in Biosensors" page 60.	
1990	SCAND J IMMUNOL, Volume 31, J. Heidrup, "A New Technique Using a Purifying Antibody Against Glycophorin-A for Purifying Floth-Paque-Septra® Leucocytes of Conspicuous Erythrocytes" page 289 - page 296, see "Materials and methods" and page 293, right column.	
1997	Rye, et al.: "Immunobead Filtration". <i>American Journal of Pathology</i> January 1997; Vol. 150, No. 1, pp. 99-107.	
1993	A. Bernick et al.: "A Rapid Method for Selecting Specific T Cell Clones using Paramagnetic Dynabeads". <i>Scand J Immunol</i> ; 1993; pp. 212-216.	
1989	Hiroshi Maeda: "Applicability of an Immuno-magnetic Bead Technique for a Forensic Identification of ABO Blood Types: The Use of Fluorescent Microspheres". <i>Am J Legal Med</i> ; 1989; 322-327.	
1996	Andrew J. Davis, et al.: "Detection of Cells by Antigen Using Antibody-Conjugated Fluorespheres (ACF): Application for Str-Color Immunofluorescence". <i>Biotechnology</i> ; 1996; 14(5):503.	
	Derwent accession no. 93-173 892, 1993 KK: "Sensitivity detection of ligand-receptor reaction by combining fluorescent fine particles with objective substance, passing mix. through flow cytometer, counting number of agglomerates etc."; & JP A 5107349, 520427, DW9321	
1985	K.A. Maibach, et al.: "Future Biotechnology: Present and Future". <i>Biotechnology</i> , April 1985; Vol. 3, pp. 337-356	
1992	W. Kemmer, et al.: "Separation of tumor cells from a suspension of dissociated human colorectal carcinoma tissue by means of monoclonal antibody-coated magnetic beads". <i>Journal of Immunological Methods</i> 1992; pp. 197-200.	
1990	C.L. Cova, et al.: "positive stem cell selection - basic sciences". <i>Progress in Clinical and Biological Research</i> , Vol. 333, 1990; pp. 385-402.	
1984	B.H. Dunlop, et al.: "Magnetic separation in biotechnology". <i>Biotech ADVS</i> , Vol. 2, 1984, pp. 66-69.	
1983	G.H. Seibell: "Magnetic Separations in Biotechnology - a Review". <i>J. Chem. Tech. Biotechnol.</i> ; Vol. 35B, No. 3, 1985, pp. 175-182.	
1991	J.M. Pizobis, et al.: "Immunomagnetic separation, primary culture, and characterization of cortical thick ascending limb plus distal convoluted tubule cells from mouse kidney". <i>National Library of Medicine, File Medicine, Medicine accession no. 07671620</i> ; Br J Haematol Mar 1991; 77 (3), pp. 267-273.	
1987	G. Kvalheim, et al.: "Elimination of B-1 lymphoma Cells from Human Bone Marrow: Model Experiments Using Monodisperse Magnetic Particles Coated with Primary Monoclonal Antibodies". <i>Cancer Research</i> ; Vol. 47, February 1987, pp. 846-851.	
1987	J.T. Kemmure, et al.: "Monoclonal antibodies and magnetic microspheres for the depletion of leukemic cells from bone marrow harvested for autologous transplantation". <i>Bone Marrow Transplantation</i> 1987; Vol. 2, pp. 133-139.	
1987	G. Kvalheim, et al.: "Immunomagnetic purging of B-lymphoma cells from human bone marrow". <i>Dialog Information service. File 139, Cancer</i> ; Dialog accession no. 00539643; Fourth European Conference on Clinical Oncology and Cancer Nursing, Nov. 1-4, 1987, Madrid, Federation of European Cancer Societies, pp. 282, 1987.	
1988	T. Lea, et al.: "Monodisperse magnetic polymer particles: their use in separation of cells and subcellular components, and in the study of lymphocyte function in vivo". <i>National Library of Medicine, File Medicine, Medicine accession no. 90234499</i> ; J. Mol. Recognit.; Feb. 1988; 1(1), pp. 9-18.	

Spied 3/30/00

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

Substitute Disclosure Statement Form (PTO-1448)

Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE

Date Mailed: October 5, 2004

Sheet 1 of 2

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 7885-55USWO	Application Number: 09/125,751
	Applicant: FODSTAD et al.	
	Filing Date: October 30, 1998	Group Art Unit: 1643

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
			"Making the most of naudin: a novel target for tumor immunotherapy", Barrett-Boyes SM, Cancer Immunol Immunother. 1996 Nov; 43(3): 142-51.			
			"The Epithelial Glycoprotein 2 (EGP-2) Promoter-driven Epithelial-specific Expression of EGP-2 in Transgenic Mice: A New Model to Study Carcinoma-directed Immunotherapy", McLaughlin et al., Cancer Research 61, 4105-4111, May 15, 2001.			
			"Selection and Characterization of Anti-MUC-1 scFvs Intended for Targeted Therapy", Wintthrop et al., Clinical Cancer Research, Vol. 9, 3845-3853a, September 1, 2003 (Suppl.).			
			"Kinetics of Uptake and Degradation of an Abrin Immunotoxin by Melanoma Cells and Studies of the Rates of Cellular Internalization", Godal et al., Int. J. Cancer: 42, 400-404 (1988).			
			"Studies on the Mechanism of Action of Abrin-9.2.27 Immunotoxin in Human Melanoma Cell Lines", Godal et al., Cancer Research 47, 6243-6247, December 1, 1987.			
			"Systematic Immunotoxin Treatment Inhibits Formation of Human Breast Cancer Metastasis and Tumor Growth in Nude Rats", Engelbrecht et al., Int. J. Cancer: 88, 970-976 (2000).			
			"A Murine cDNA Encodes a Pan-Epithelial Glycoprotein that is also Expressed on Plasma Cells", Borgsgel et al., The Journal of Immunology, Vol. 148, 590-596, No. 2, January 15, 1992.			
			"Molecular cloning of cDNA for the carcinoma-associated antigen CA733-2", Szabo et al., Proc. Natl. Acad. Sci. USA, Vol. 87, pp. 3542-3546, May 1990 Biochemistry.			
			"Molecular Cloning and Characterization of a Human Adenocarcinoma/Epithelial Cell Surface Antigen Complementary DNA", Strnad et al., Cancer Research 49, 314-317, January 15, 1989.			
			Appendix 3-6, "Monoclonal Antibody BM7" and Appendix 3-7, "Monoclonal Antibody BM2", Brummend et al., Cancer Research, 1994, 54: 4162-4168			
			"Pharmacokinetics and Scintigraphy of Indium-111-DTPA-MOC-31 in Small-Cell Lung Carcinoma", Kosterink et al., The Journal of Nuclear Medicine- Vol. 36, No. 12, December 1995.			
			"Can therapeutic concentrations of the anti EGP2 immunotoxin conjugate MOC31-PE be achieved in patients with antigen positive carcinomas? A phase I study in patients with advanced mammary, lung, colorectal or prostate carcinoma", Aamdal et al., pp. 1-24.			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1448)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE